Stock Spotlight: Merck has had a Lazarus-like turn-around thanks to cost-cutting, new products and a savvy legal strategy. Is it still a buy? NEW YORK (CNNMoney.com) -- Merck has enjoyed a strong comeback since the messy Vioxx blowout nearly three years ago. But you might be … [Read more...] about Merck’s Post-Vioxx comeback